WHO WE ARE

Oncofibro is a commercial-stage biotechnology company developing advanced therapies for companion animals and advancing late-stage clinical programs for human health. Our pipeline includes Krysaygio™, a first-in-class, autologous ex vivo T Cell therapy currently in clinical evaluation.

Our lead assets are built on pioneering research in cellular signaling and fusion protein engineering, developed by our co-founder Dr Yosef Rafaeli. These innovations were initially developed and patented under Invictus Biotech Solutions (formerly Taiga Biotechnology).

Our Name

Oncofibro is a portmanteau of two words representing our focus on developing first-in-class modalities for Oncology and Fibrosis. We are targeting oncology in both humans and companion animals. We take a platform approach with our focus in humans specific to lung diseases.